Provided By GlobeNewswire
Last update: Aug 27, 2025
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
Read more at globenewswire.comNASDAQ:DYN (9/26/2025, 10:21:03 AM)
12.8
+0.22 (+1.75%)
Find more stocks in the Stock Screener